GSK Sells Lucozade, Ribena, To Japan’s Suntory Beverage For $2.1 B
This article was originally published in PharmAsia News
Selling its Lucozade and Ribena drink for a £1.35 billion ($2.11 billion) to Japan's Suntory Beverage & Food Ltd gives Glaxo a welcome return and a narrower focus on its consumer health operations, which together should help the British drug maker’s top objective of delivering on its late-stage pipeline.
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.